Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by Pacer Advisors Inc.

Pacer Advisors Inc. decreased its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 8.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,597,456 shares of the specialty pharmaceutical company's stock after selling 155,426 shares during the quarter. Pacer Advisors Inc. owned about 2.89% of Supernus Pharmaceuticals worth $57,764,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. GAMMA Investing LLC raised its holdings in Supernus Pharmaceuticals by 97.1% in the 3rd quarter. GAMMA Investing LLC now owns 808 shares of the specialty pharmaceutical company's stock valued at $25,000 after acquiring an additional 398 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Supernus Pharmaceuticals by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company's stock valued at $61,000 after purchasing an additional 352 shares during the last quarter. KBC Group NV lifted its position in Supernus Pharmaceuticals by 53.1% during the fourth quarter. KBC Group NV now owns 2,679 shares of the specialty pharmaceutical company's stock worth $97,000 after buying an additional 929 shares in the last quarter. Kennebec Savings Bank acquired a new position in Supernus Pharmaceuticals during the third quarter worth $103,000. Finally, Janney Montgomery Scott LLC purchased a new stake in Supernus Pharmaceuticals in the 4th quarter valued at $211,000.

Insider Buying and Selling at Supernus Pharmaceuticals

In related news, VP Padmanabh P. Bhatt sold 700 shares of the company's stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $39.62, for a total transaction of $27,734.00. Following the sale, the vice president now directly owns 10,149 shares of the company's stock, valued at $402,103.38. This represents a 6.45 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Frank Mottola sold 15,000 shares of the firm's stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $36.98, for a total transaction of $554,700.00. Following the completion of the transaction, the senior vice president now directly owns 8,200 shares of the company's stock, valued at $303,236. This represents a 64.66 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 154,913 shares of company stock valued at $5,687,914 over the last quarter. 9.30% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several research firms have recently commented on SUPN. Cowen reiterated a "buy" rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. Cantor Fitzgerald started coverage on shares of Supernus Pharmaceuticals in a research note on Monday, January 6th. They set an "overweight" rating and a $57.00 target price on the stock. Finally, Piper Sandler restated a "neutral" rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th.

Supernus Pharmaceuticals Price Performance

Shares of NASDAQ:SUPN traded down $0.34 during midday trading on Friday, reaching $38.35. 199,506 shares of the company's stock were exchanged, compared to its average volume of 319,466. The stock has a market cap of $2.12 billion, a price-to-earnings ratio of 35.84 and a beta of 0.90. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $25.53 and a fifty-two week high of $39.88. The firm's 50 day simple moving average is $37.10 and its two-hundred day simple moving average is $34.39.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last announced its quarterly earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share for the quarter, beating analysts' consensus estimates of $0.44 by $0.25. Supernus Pharmaceuticals had a net margin of 9.16% and a return on equity of 7.79%. The business had revenue of $175.70 million during the quarter, compared to analysts' expectations of $157.35 million. During the same period last year, the business earned ($0.29) earnings per share. The business's revenue for the quarter was up 14.2% on a year-over-year basis. Equities research analysts predict that Supernus Pharmaceuticals, Inc. will post 2.37 earnings per share for the current fiscal year.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.